Copper and Copper-Based Nanoparticles in Medicine-Perspectives and Challenges.

antibacterial properties antiviral properties cancer therapy copper nanoparticles drug delivery systems perspectives

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
18 Sep 2023
Historique:
received: 29 08 2023
revised: 16 09 2023
accepted: 16 09 2023
medline: 29 9 2023
pubmed: 28 9 2023
entrez: 28 9 2023
Statut: epublish

Résumé

Nanotechnology has ushered in a new era of medical innovation, offering unique solutions to longstanding healthcare challenges. Among nanomaterials, copper and copper oxide nanoparticles stand out as promising candidates for a multitude of medical applications. This article aims to provide contemporary insights into the perspectives and challenges regarding the use of copper and copper oxide nanoparticles in medicine. It summarises the biomedical potential of copper-based nanoformulations, including the progress of early-stage research, to evaluate and mitigate the potential toxicity of copper nanomaterials. The discussion covers the challenges and prospects of copper-based nanomaterials in the context of their successful clinical translation. The article also addresses safety concerns, emphasizing the need for toxicity assessments of nanomedicines. However, attention is needed to solve the current challenges such as biocompatibility and controlled release. Ongoing research and collaborative efforts to overcome these obstacles are discussed. This analysis aims to provide guidance for the safe and effective integration of copper nanoparticles into clinical practice, thereby advancing their medical applications. This analysis of recent literature has highlighted the multifaceted challenges and prospects associated with copper-based nanomaterials in the context of their translation from the laboratory to the clinic. In particular, biocompatibility remains a formidable hurdle, requiring innovative solutions to ensure the seamless integration into the human body. Additionally, achieving the controlled release of therapeutic agents from copper nanoparticles poses a complex challenge that requires meticulous engineering and precise design.

Identifiants

pubmed: 37764463
pii: molecules28186687
doi: 10.3390/molecules28186687
pmc: PMC10536384
pii:
doi:

Substances chimiques

cuprous oxide T8BEA5064F
Copper 789U1901C5
Delayed-Action Preparations 0
Oxides 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Nanomaterials (Basel). 2021 Aug 31;11(9):
pubmed: 34578571
Nanomaterials (Basel). 2021 Dec 10;11(12):
pubmed: 34947695
RSC Adv. 2022 Feb 3;12(7):4428-4436
pubmed: 35425445
Front Surg. 2022 Aug 05;9:905892
pubmed: 35990090
Bratisl Lek Listy. 2019;120(6):397-409
pubmed: 31223019
Nanomaterials (Basel). 2022 Jun 22;12(13):
pubmed: 35807977
ACS Omega. 2019 Feb 05;4(2):2637-2648
pubmed: 31459499
Sci Rep. 2022 Sep 28;12(1):16165
pubmed: 36171339
Biometals. 2021 Dec;34(6):1217-1235
pubmed: 34398357
Med Hypotheses. 2020 Sep;142:109814
pubmed: 32388476
J Clin Med. 2019 Dec 29;9(1):
pubmed: 31905769
Artif Cells Nanomed Biotechnol. 2021 Dec;49(1):240-249
pubmed: 33719804
Environ Toxicol Pharmacol. 2019 Oct;71:103220
pubmed: 31306862
Polymers (Basel). 2023 May 20;15(10):
pubmed: 37242968
J Nanobiotechnology. 2018 Sep 19;16(1):71
pubmed: 30231877
Nanomaterials (Basel). 2021 Dec 22;12(1):
pubmed: 35009968
Nanomaterials (Basel). 2022 Jan 14;12(2):
pubmed: 35055284
Sci Rep. 2020 Jan 8;10(1):1
pubmed: 31913322
Adv Mater. 2022 May;34(21):e2201043
pubmed: 35427430
Nanoscale Res Lett. 2020 May 20;15(1):115
pubmed: 32436107
EJNMMI Res. 2020 Jun 30;10(1):73
pubmed: 32607918
J Pers Med. 2022 Apr 22;12(5):
pubmed: 35629095
Antimicrob Agents Chemother. 2008 Feb;52(2):518-25
pubmed: 18070974
Antibiotics (Basel). 2023 Jul 29;12(8):
pubmed: 37627671
Antimicrob Resist Infect Control. 2019 Jan 5;8:3
pubmed: 30627427
Sci Rep. 2023 Jun 6;13(1):9202
pubmed: 37280318
Front Oncol. 2022 Jul 14;12:930125
pubmed: 35912195
Proc Natl Acad Sci U S A. 2021 Oct 19;118(42):
pubmed: 34654743
ACS Biomater Sci Eng. 2017 Dec 11;3(12):3183-3194
pubmed: 33445360
Nanomaterials (Basel). 2020 Dec 19;10(12):
pubmed: 33352731
Top Curr Chem (Cham). 2020 May 7;378(3):40
pubmed: 32382832
Microb Drug Resist. 2021 May;27(5):616-627
pubmed: 33048008
Front Mol Biosci. 2021 Aug 24;8:711227
pubmed: 34504870
Front Bioeng Biotechnol. 2022 Sep 01;10:941109
pubmed: 36118563
PLoS One. 2022 Aug 2;17(8):e0272307
pubmed: 35917302
J Photochem Photobiol B. 2019 Aug;197:111556
pubmed: 31326842
Nanomedicine. 2023 Jan;47:102620
pubmed: 36265559
Iran J Microbiol. 2023 Feb;15(1):138-148
pubmed: 37069916
ACS Omega. 2023 Apr 10;8(16):14290-14320
pubmed: 37125102
J Trace Elem Med Biol. 2022 Jul;72:126977
pubmed: 35397331
Int J Mol Sci. 2023 Jun 22;24(13):
pubmed: 37445681
Angew Chem Int Ed Engl. 2021 Jun 1;60(23):13073-13080
pubmed: 33837622
Cells. 2020 Mar 10;9(3):
pubmed: 32164376
Biol Trace Elem Res. 2023 Nov;201(11):5278-5297
pubmed: 36905557
J Nanobiotechnology. 2022 Mar 2;20(1):98
pubmed: 35236363
J Biosci Bioeng. 2012 May;113(5):580-6
pubmed: 22227118
J Pharm Investig. 2023;53(1):19-33
pubmed: 36568502
PeerJ. 2021 Nov 19;9:e12392
pubmed: 34820175
Sci Rep. 2019 Aug 30;9(1):12613
pubmed: 31471546
Sci Rep. 2022 Mar 22;12(1):4835
pubmed: 35318357
Int J Nanomedicine. 2020 Apr 16;15:2541-2553
pubmed: 32368039
Biomater Sci. 2018 Nov 20;6(12):3219-3230
pubmed: 30255863
Biomed Rep. 2021 May;14(5):42
pubmed: 33728048
J Mech Behav Biomed Mater. 2022 Feb;126:105017
pubmed: 34894497
Int J Nanomedicine. 2023 Jun 19;18:3339-3358
pubmed: 37361387
Biochem Biophys Res Commun. 2019 Oct 1;517(4):684-690
pubmed: 31400855
Adv Drug Deliv Rev. 2023 Aug;199:114900
pubmed: 37263543

Auteurs

Marta J Woźniak-Budych (MJ)

NanoBioMedical Centre, Adam Mickiewicz University in Poznan, Wszechnicy Piastowskiej 3, 61-614 Poznan, Poland.

Katarzyna Staszak (K)

Institute of Technology and Chemical Engineering, Poznan University of Technology, 60-965 Poznan, Poland.

Maciej Staszak (M)

Institute of Technology and Chemical Engineering, Poznan University of Technology, 60-965 Poznan, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH